India’s Biocon To Buck Trend, Make R&D Wholly Owned Subsidiary
This article was originally published in PharmAsia News
Executive Summary
Indian biotech Biocon is rejecting the path of many of its pharmaceutical colleagues and making its research and development unit into a wholly owned subsidiary. Other Indian pharmaceutical firms have been spinning off their R&D operations into separate companies in recent years, but a source said Biocon management considers R&D an integral part of its business. Analysts also say the move, scheduled for later this year, would help Biocon reduce its generics risk profile. (Click here for more